Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06336330

Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germany

Heart failure (HF) is a global, public health issue that affects more than 63 million people worldwide; this burden is expected to increase substantially as the population ages. Despite advancements in treatment, a HF diagnosis still leads to significant morbidity and mortality; there is also an immense impact on patients' health-related quality of life (HRQoL). Dapagliflozin was recently granted approval for heart failure by the European Commission, regardless of ejection fraction and whether the patient has diabetes. Real-world observational data are necessary to describe dapagliflozin use in real-world settings in order to assess treatment patterns, HF symptoms and their impact on physical limitation, HRQoL and work productivity, as well as health care utilization of patients treated with dapagliflozin in this setting under local treatment standard conditions in Germany.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Heart Diseases Cardiovascular Diseases Heart Failure

Age range

18 year–130 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Aachen, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years as of study index date; the study index date is date of initiation of treatment with dapagliflozin
  • Patient received/receiving treatment with dapagliflozin in accordance with the local dapagliflozin product label for symptomatic chronic heart failure (HF) and at timepoint of dapagliflozin initiation with:
  • preserved ejection fraction (HFpEF; EF≥50%) OR mildly reduced ejection fraction (HFmrEF; EF 41-49%)
  • OR reduced ejection fraction (HFrEF EF ≤40%)
  • Patient is enrolled within 14 to 90 days following initiation of dapagliflozin
  • Signed and dated informed consent prior to enrolment in the study

Exclusion criteria

  • Patient should not be enrolled if he/she is less than 14 days or more than 90 days following initiation of dapagliflozin
  • Prior treatment with dapagliflozin or other SGLT2i treatment
  • Initiation of dapagliflozin outside of the local HF label
  • Diagnosis of Type 1 diabetes prior to enrolment
  • Current or planned participation in a clinical trial using an investigational medical product for treating HF
  • Patient is involved in the planning and/or conduction of the study
  • Hypersensitivity to dapagliflozin or to any of the excipients listed in the SmPC

Treatment and study plan

Primary outcomes

  1. Time to discontinuation of dapagliflozin

    Time frame: Baseline to 12 months

    Time from dapagliflozin treatment initiation until the time at which participants stop taking the medication for any reason (from the perspective of the prescriber).

  2. Reasons for discontinuation of dapagliflozin

    Time frame: Baseline to 12 months

    Reasons for discontinuation (from the perspective of the prescriber) of patients initiated on dapagliflozin for HF will be described.

  3. Dose changes of dapagliflozin

    Time frame: Baseline to 12 months

    The number of participants with doses changes for dapagliflozin

  4. Number of patients with dapagliflozin treatment interruptions

    Time frame: Baseline to 12 month

    The number of participants who discontinue treatment with dapagliflozin.

  5. Treatment switches from dapagliflozin to other SGLT2i

    Time frame: Baseline to 12 months

    The number of participants who switch from dapagliflozin to another SGLT2i (Sodium-glucose cotransporter-2 inhibitor) treatment for HF.

  6. Time to other heart failure treatment discontinuation

    Time frame: Baseline to 12 months

    Time from initiation of heart failure medication other than dapagliflozin until the time at which participants discontinued treatment with that medication.

  7. Number of other heart failure treatment initiation

    Time frame: Baseline to 12 months

    The number of participants who initiate new heart failure medication other than dapagliflozin.

  8. Number of other heart failure treatment dosage changes

    Time frame: Baseline to 12 months

    The number of participants with dosage changes for heart failure medication other than dapagliflozin.

  9. Number of other heart failure treatment discontinuation

    Time frame: Baseline to 12 months

    The number of participants who discontinue treatment with heart failure medication other than dapagliflozin.

  10. Number of glucose lowering medication initiation

    Time frame: Baseline to 12 months

    The number of participants who initiate new glucose lowering medication other than dapagliflozin.

  11. Number of glucose lowering medication dosage changes

    Time frame: Baseline to 12 months

    The number of participants with dosage changes for glucose lowering medication other than dapagliflozin.

  12. Number of glucose lowering medication discontinuation

    Time frame: Baseline to 12 months

    The number of participants who discontinue treatment with glucose lowering medication other than dapagliflozin.

Secondary outcomes

  1. Absolute change from baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) score

    Time frame: Measured at 3, 6, 9 and 12 months

    The KCCQ is a 23-item questionnaire that quantifies physical limitations, self-efficacy, social interference and quality of life. Several summary scores may be calculated including: Total Symptom score (measuring symptom frequency and symptom burden), Physical limitation score (measuring limitations in common physical activities), Clinical Summary score (measure of physical limitations and total symptoms), and an Overall Summary score (measure of physical limitations, total symptoms, HRQoL, and social limitations). Summary scores will be examined at each assessment point during follow-up.

  2. Absolute change from baseline in Medication Adherence Report Scale (MARS)-5 questionnaire

    Time frame: Measured at 3, 6, 9 and 12 months

    The MARS-5 is five-item self-report adherence scale which assesses both intentional and non-intentional non-adherence. Respondents rate the frequency with which the five different medication-taking behaviours occur, scoring each item on a 1-5-point scale with higher scores indicating higher reported adherence. The MARS-5 has been shown to be reliable and valid across a variety of health conditions, including cardiovascular and pulmonary diseases.

  3. Absolute change from baseline in Work Productivity and Activity Impairment (WPAI) score

    Time frame: Measured at 3, 6, 9 and 12 months

    The WPAI is a validated instrument to measure impairments in paid and unpaid work and activities. It measures absenteeism (work time missed), presenteeism (impairment at work / reduced on-the-job effectiveness) as well as the impairments in unpaid activity because of health problems during the past seven days. It has been validated to quantify work impairments for numerous diseases such as asthma, psoriasis, irritable bowel syndrome, and Crohn's disease, but has not yet been validated for use in heart failure participants. Scores will be derived from the overall work impairment at each timepoint and then changes of from baseline will be reported.

Other outcomes

  1. The absolute change from baseline in occurrence of depressions in patients initiated on dapagliflozin for HF as captured by the Patient Health Questionnaire-9 (PHQ-9)

    Time frame: Measured at 3, 6, 9 and 12 months

    The PHQ-9 comprises 9 items that capture depressed mood and anhedonia. It has been validated as a screening tool with good evidence of responsiveness. The PHQ-9 score is obtained by adding the score for each question (total points). PHQ-9 score ≥10 showed a sensitivity of 88% and a specificity of 88% for major depression. PHQ-9 scores of 5, 10, 15, and 20 have been shown to represent mild, moderate, moderately severe, and severe depression, respectively.

  2. Healthcare resource utilisation - Number of hospitalisations since dapagliflozin initiation

    Time frame: Measured at 3, 6, 9 and 12 months

    The number of patients hospitalised will be examined at each assessment point.

  3. Healthcare resource utilisation - Length of HF-related hospital stay since dapagliflozin initiation

    Time frame: Measured at 3, 6, 9 and 12 months

    Duration of outpatient clinic visits in days, will be examined at each assessment point.

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

Early Treatment of Heart Failure: a Non-interventional Study Program of Patients With Heart Failure and Initiated on Dapagliflozin (EVOLUTION-HF DEallEF)

Acronym: EvolutionHF-DE

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Mar 28, 2024
Registry last updated
Jul 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.